Anti–Interleukin‐2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation
David R. Nelson, Consuelo Soldevila‐Pico, Alan Reed, Manal F. Abdelmalek, Alan W. Hemming, Willem J. van der Werf, Richard Howard, Gary L. Davis – 30 December 2003 – The pathogenesis of hepatitis C virus (HCV) recurrence after liver transplantation (LT) is poorly understood, but the cellular immune response is likely to have a major role. Daclizumab, an interleukin‐2 receptor (IL‐2R) antibody that blunts T‐cell activation, leading to a decreased risk for cellular rejection, is used frequently in transplant recipients.